FDA amends opioid action warning

Share this article:
The Food and Drug Administration will temporarily allow the continued production, marketing and distribution of one particular type of opioid, which is widely used to alleviate pain in terminally ill patients.

The action is in response to a March 30 warning that it issued to manufacturers to stop producing certain unapproved prescription opioids.  Concerns from palliative care patients and healthcare professionals prompted the FDA to amend the warning. They were concerned that the original order would cause a shortage of morphine sulfate oral solution.

The agency has determined that the 20 milligram dosage form of morphine sulfate oral solution is medically necessary and should remain on the market until an approved alternative becomes available.

Share this article:

More in News

Skilled nursing facilities with poor quality ratings do not readmit more patients to hospitals, researchers find

Skilled nursing facilities with poor quality ratings do ...

Low-quality and high-quality skilled nursing facilities readmit about the same proportion of residents to hospitals, suggest research findings recently published in the American Journal of Medical Quality.

Cipro and related antibiotics increase MRSA risk in long-term care facilities, study ...

Long-term care residents on a fluoroquinolone antibiotic such as Cipro are at an increased risk for methicillin-resistant Staphylococcus aureus, researchers in France have found.

Jonathan Blum, who oversaw long-term care reforms, resigns as head of Medicare

The nation's top Medicare official, Jonathan Blum, is leaving his post next month, news outlets reported Tuesday. Blum became a familiar figure to long-term care providers through Open Door Forum calls and other outreach efforts during his five-year tenure, as he guided implementation of Medicare ...